Table 2.
Kidney Recipient and Donor Demographics and Clinical Factors in Recipients Receiving Cyclosporine (n=744)
| Young Age (18–34 years, n=107) | Middle Age (35–64 years, n=520) | Old Age (65–84 years, n=117) | |
|---|---|---|---|
| Recipient age, median (range) | 26.9 (18–34.7) | 51.7 (35–65) | 69.0 (65.3–81.3) |
| Recipient gender, male | 71 (66.4%) | 321 (61.7) | 67 (57.3%) |
| Recipient African American | 17 (15.9%) | 64 (12.3%) | 5 (4.3%) |
| Recipient weight (kg), median (range) | 81.8 (37.7–158.0) | 82.0 (39.0–150.3) | 78.2(44.2–136.4) |
| Prior kidney transplant | 15 (14.0%) | 77 (14.8%) | 6 (5.1%) |
| Primary cause of kidney failure | |||
| diabetes mellitus | 8 (7.5%) | 159 (30.6%) | 39 (33.3%) |
| glomerulonephritis | 35 (32.7%) | 125 (24.0%) | 12 (10.3%) |
| polycystic kidney disease | 1 (.93%) | 67 (12.9%) | 14 (12.0%) |
| hypertension | 4 (4.0%) | 43 (8.3%) | 25 (21.4%) |
| others | 50 (46.8%) | 105 (20.2%) | 21 (18.0%) |
| unknown | 9 (8.4%) | 21 (4.0%) | 6 (5.1%) |
| Diabetes at time of transplant | 13 (12.2%) | 195 (37.5%) | 52 (44.4%) |
| SPK1 | 0 (0.0%) | 9 (1.7%) | 0 (0.0%) |
| Donor age, median (range) | 37.6 (6.1–65.3) | 41.9 (2.9–66) | 46.4 (0.8–69.4) |
| Donor gender, male | 44 (41.1%) | 241 (46.4%) | 53 (45.3%) |
| Living donor | 83 (77.6%) | 326 (62.9%) | 66 (56.4%) |
| Dialysis after transplantation2 | 4 (3.7%) | 69 (13.3%) | 17 (14.5%) |
| Calcium channel blocker use3,4 | 857 (51.4%) | 4150 (54.0%) | 1089 (61.2%) |
| Prophylactic antiviral use 3 | 911 (55.2%) | 3945 (51.3%) | 894 (50.3%) |
| ACE inhibitor use3 | 291 (17.5%) | 1251(16.3%) | 253 (14.2%) |
| Steroid use3 | 766 (46.0%) | 4046 (53.0%) | 922 (52.5%) |
1
simultaneous pancreas kidney transplant
2
one or more dialysis sessions within first 30 days posttransplant in living and deceased subjects
3
drug from this class use at the time of trough measurement
4
calcium channel blocker was present at time of trough measurement; primarily amlodipine and diltiazem.